FDA Harvests Data Using IO Informatics’ Sentient Software
News Jan 21, 2010
IO Informatics, Inc. announces an agreement to license its Sentient Suite of Life Science & Healthcare software to the FDA Center for Veterinary Medicine.
“We are pleased to have the Sentient system deployed at the FDA,” stated Robert Stanley, President and CEO of IO Informatics. “Sentient is a powerful data integration and knowledge building suite that will make it possible for the FDA to conduct reliable toxicity assessment in less time and for lower cost, specifically by enabling them to move more effectively from animal studies to cell cultures – reducing the number of live animals required to produce meaningful knowledge. Among the advantages they have identified are the ease of implementing Sentient to pull in data from a variety of sources and formats, as well as its accessibility and ease of use for researchers and managers. These capabilities will allow them to quickly get a better handle on projects and make it easier to achieve success in research.”
At the FDA, Sentient will allow researchers to acquire, digest and access data from genomics (RNA, µRNA), and proteomics (serum proteome: abundance & activity) in multiple tissues (blood, liver, kidney).
In addition, through the use of the Sentient framework, scientists will be able to conduct tissue analytics from biopsies (liver, kidney) more efficiently and accurately and will be provided with animal genotyping for response correlation.
Via the Sentient suite of software, researchers will share and access experimental data from microarrays (genomics), 2DE gels (proteomics), mass spectrometry, microscopy (tissue images), pK assays (blood chemistry) and combined genetic/phenotypic/visual animal classification.
The Sentient environment is used to identify and qualify multi-modal, cross-species-specific toxicity biomarkers. This provides an intimate understanding of biological systems and ‘connects the dots’ for toxicity responses common to animal and tissue cultures, despite the involvement of many incomparable pathways.
As a result, the Veterinary Center researchers will be able to confidently determine toxicity with easier to handle cell cultures, at a much faster turnover (as the reproductive cycle is extremely short; long-term effects can be studied effectively). Using these methods, many different experimental layouts can be pursued in parallel and at significantly lower operating costs, due to the decrease in the live animal facilities needed.
New Inherited Neurodevelopmental Disease DiscoveredNews
Researchers have identified a new inherited neurodevelopmental disease that causes slow growth, seizures and learning difficulties in humans.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE